Furthermore, we demonstrated that the addition of CX3CL1 to a non-immunogenic dose of MTX-treated dying cancer cells is sufficient to elicit an immunogenic response in a tumour prophylactic mouse model, thereby revealing CX3CL1 as a power switch of immunogenic apoptosis induced by MTX (Figure 2D). The gene discussed is CX3CL1; the disease is cancer.